Kura Oncology (KURA) Operating Expenses (2010 - 2026)

Kura Oncology (KURA) has 17 years of Operating Expenses data on file, last reported at $97.1 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 23.19% year-over-year to $97.1 million in Q1 2026; TTM through Mar 2026 was $97.1 million, a 64.23% decrease from a year earlier, with the FY2025 full-year figure at $371.1 million, up 50.2% from the prior year.
• Operating Expenses for Q1 2026 stood at $97.1 million, up from $78.8 million in the prior quarter.
• Over the last five years, Operating Expenses for KURA reached as high as $97.1 million in Q1 2026 and fell as low as $32.8 million in Q1 2022.
• Historically, Operating Expenses has averaged $52.0 million across 5 years, with a median of $44.6 million in 2023.
• Across the five-year window, Operating Expenses grew 5.01% in 2022 and surged 63.25% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $35.2 million in 2022, then surged by 33.01% to $46.8 million in 2023, then soared by 63.25% to $76.3 million in 2024, then advanced by 3.24% to $78.8 million in 2025, then rose by 23.19% to $97.1 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $97.1 million in Q1 2026, $78.8 million in Q1 2025, and $76.3 million in Q4 2024.